The Renin-Angiotensin System in Essential Hypertension

Condition(s) targeted: Hypertension

Intervention: Enalapril 20 mg bd (Drug); Candesartan 8 mg bd (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: St George's, University of London

Official(s) and/or principal investigator(s):
Timothy WR Doulton, BSc MRCP, Principal Investigator, Affiliation: SGUL

Overall contact:
Timothy WR Doulton, BSc MRCP, Phone: +44 208 725 3176, Ext: -, Email: tdoulton@sgul.ac.uk

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Official title: The Renin-Angiotensin System in Essential Hypertension

Study design: Other, Randomized, Open Label, Active Control, Crossover Assignment

Primary outcome:

Change in BP

Change in PRA and aldosterone

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Essential Hypertension

- SBP 140-159 mmHg

- DBP 90-99 mmHg

Exclusion Criteria:

- Intolerance of or allergy to ACE Inhibitors or ARBS

- Pregnant or Breastfeeding

- Pre-menopausal women

- Uncontrolled cardiac or renal failure

- Diabetes mellitus

Timothy WR Doulton, BSc MRCP, Phone: +44 208 725 3176, Ext: -, Email: tdoulton@sgul.ac.uk

Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL, LONDON SW17 0RE, United Kingdom; Recruiting
Timothy WR Doulton, BSc MRCP, Phone: +44 208 725 3176, Ext: -, Email: tdoulton@sgul.ac.uk
Timothy WR Doulton, BSc MRCP, Principal Investigator

Starting date: April 2004
Ending date: October 2006
Last updated: May 10, 2007